{"id":3391,"date":"2026-04-24T21:06:46","date_gmt":"2026-04-24T21:06:46","guid":{"rendered":"https:\/\/pge2-hypothesis.com\/?page_id=3391"},"modified":"2026-09-02T05:49:19","modified_gmt":"2026-09-02T05:49:19","slug":"lc-trials","status":"publish","type":"page","link":"https:\/\/pge2-hypothesis.com\/?page_id=3391","title":{"rendered":"LC trials"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Long COVID therapies, tested partially beneficial, linked to EP-receptor profiles <\/h2>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\n


Long COVID interventions; PGE2 hypothesis-driven mechanistic explanations<\/p>\n\n

\n\n\n\n\n\n\n\n\n\n\n\n
\u00a0<\/strong> Long COVID therapy trials<\/strong><\/td>\n\u00a0<\/strong> Published data<\/td>\n\u00a0<\/strong> Hypothetical molecular mechanisms underlying symptom alleviation in LC

<\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n

DNA Aptamer drug BC007<\/strong> Rovunaptabin<\/strong> \u00a0<\/strong> Two cohort studies
1,2<\/sup>
and a case report 3<\/sup> \u00a0 \u201cThe removal of GPCR-AAb might ameliorate the characteristics of the LCD, such as capillary impairment, loss of taste, and CFS.\u201d 3<\/sup>

<\/td>\n
BC007
decreases IgG-autoantibody-activity 3<\/sup> \u00a0 PGE2 stimulates autoantibodies through EP2 and EP4 4<\/sup> 5<\/sup> 6,7<\/sup> \u00a0<\/td>\n		\n


BC007 could decrease inflammatory PGE2 activity, neutralizing autoantibodies (see PGE2 in autoimmunity<\/a>)<\/p>\n

Potentially beneficial for patients with \u201cEP2 up\u201d and\/or \u201cEP4 up\u201d (\u201cEP3 down\u201d)<\/p>\n<\/td>\n<\/tr>\n


Histamine receptor antagonists (HRA)

<\/strong> Cohort study 8<\/sup>

\u201c72% of patients with long COVID who received HRA reported clinical improvement.\u201d \u00a0<\/strong><\/td>\n
HRA could decrease inflammatory PGE2 activity\u00a0 8<\/sup>
Histamine reportedly upregulates COX-2\/ PGE2 through H1 9<\/sup> and through H2 10<\/sup> \u00a0 HRA therapy antagonizes histamine activity 8<\/sup>

<\/td>\n
HRA could decrease inflammatory PGE2 activity by preventing histamine from upregulating PGE2 through H1 and H2 \u00a0

Potentially beneficial for patients with \u201cEP3 down\u201d

<\/td>\n<\/tr>\n

Hyperbaric oxygen (HBOT)<\/strong> \u00a0<\/strong> Cohort study 11<\/sup> Review 12<\/sup>

\u201c56-63% of long term-ill patients had a clinically relevant improvement in MCS\/PCS 3 months after HBOT. However, 13-19% of the patients had a clinically relevant deterioration in MCS\/PCS.\u201d <\/strong>11<\/sup><\/strong>

<\/strong><\/td>\n
HBOT decreases PGE2 level 13-15<\/sup>
HBOT alleviates predominantly cognitive symptoms 11<\/sup> that we presume to be stimulated by EP1 (see section 10. And 11.1)
\u201cThe symptoms that showed most improvement were predominantly in the cognitive domain 11<\/sup>.\u201d<\/td>\n		\n


HBOT decreases inflammatory PGE2 activity effectively 13-15<\/sup> HBOT elevates BP 16<\/sup>
BP is elevated through EP317<\/sup>
\u00a0
Potentially beneficial for patients with \u201cEP1 up\u201d<\/p>\n

Potentially harmful for patients with \u201cEP3 up\u201d & \u201cEP1 down\u201d

<\/strong>Potentially safe for patients with \u201cEP3 down\u201d

<\/p>\n<\/td>\n<\/tr>\n


Lidocaine
<\/strong>Subcutaneous lidocaine-HP-\u03b2-CD: every other day or daily \u00a0<\/strong> Cohort study 18<\/sup>

\u201cTwenty-seven of 30 symptoms improved significantly at week 24 of treatment compared to pre-treatment. No serious adverse events were reported.\u201d 18<\/sup>

<\/td>\n
Prolonged Lidoca\u00efne administration reportedly decreases COX-2 \/ PGE2 activity 19<\/sup>

<\/td>\n
Prolonged Lidoca\u00efne administration could hypothetically alleviate long COVID symptoms, decreasing PGE2 activity by binding to the Gq subunit of EP1\u00a0\u00a0<\/strong>

Potentially beneficial for patients with \u201cEP1 up\u201d potentially unbeneficial for patients with \u201cEP1 down\u201d<\/strong>

<\/td>\n<\/tr>\n

Low Dose Naltrexon<\/strong> \u00a0<\/strong> Cohort study 20<\/sup> Case series with CFS patients 21<\/sup>

\u201cWe found a subset of 52\u00a0% of patients to be responders after 12 weeks of treatment.\u201d\u00a0

Case series with CFS patients 21<\/sup> \u201csmall-scale clinical trials have shown efficacy and low toxicity.\u201d

<\/td>\n
LDN decreases PGE2 activity through antagonizing TRL-4 activity 22<\/sup> \u00a0 TRL-4 triggers PGE2 production 23<\/sup><\/td>\n
LDN could decrease inflammatory PGE2 activity through antagonizing TRL-4 activity 22<\/sup>

Potentially beneficial for patients with \u201cEP3 down\u201d

<\/td>\n<\/tr>\n
Stellate Ganglion Block (SGB)<\/strong> \u00a0<\/strong> Cohort study 24<\/sup> \u00a0 \u201cResults indicated that a substantial proportion of patients (86%) experienced a reduction of their symptoms following SGB treatment.\u201d 24<\/sup><\/td>\nIn general, the SNS and PNS have opposing effects, and they interact 25<\/sup> possibly through PGE2 activity:
PGE2 binding to EP3 increases inflammatory SNS activity 26<\/sup> 27<\/sup> and suppresses PNS activity 28<\/sup>
(see section 4.) \u00a0<\/td>\n		SGB could decrease inflammatory PGE2 activity by inhibiting inflammatory SNS signaling 29<\/sup> and stimulating anti-inflammatory PNS signaling

May provide benefits across all four sub-phenotypes, but as it is expected to reduce PGE2 levels very effectively, it may pose a risk of raising blood pressure in patients with an \u201cEP3-up\u201d profile.<\/strong><\/td>\n<\/tr>\n

Vagal Nerve Stimulation (VNS)<\/strong> \u00a0<\/strong> Cohort study 30<\/sup>

\u201cThis pilot study provides preliminary evidence supporting the potential of t-VNS as a therapeutic intervention for female Long COVID patients.\u201d

<\/td>\n
PGE2 binding to EP3 suppresses PNS activity 28<\/sup>\u00a0 and increases inflammatory SNS activity 26<\/sup> 27
<\/sup>
\u00a0 VNS decreases brain COX-2\/PGE2 31<\/sup><\/strong><\/td>\n
VNS could decrease inflammatory PGE2 activity by stimulating anti-inflammatory PNS signaling decreasing inflammatory SNS activity

May provide benefits across the four sub-phenotypes for patients with an “EP1-up” profile<\/strong> as expression of EP1 is expected to decrease with decerasing COX2\/PGE2 levels in the brain and nervoussystem.\u00a0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n\n

1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hohberger, B. et al.<\/em> Safety, tolerability and clinical effects of rovunaptabin, also known as BC007 on fatigue and quality of life in patients with Post-COVID syndrome (reCOVer): a prospective, exploratory, placebo-controlled, double-blind, randomised phase IIa clinical trial (RCT). EClinicalMedicine<\/em> 86<\/strong>, 103358 (2025). https:\/\/doi.org\/10.1016\/j.eclinm.2025.103358<\/a><\/p>\n\n

2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Mardin, C. Y. et al.<\/em> Influence on eye displacement in MRI after Rovunaptabin (BC007) in Post-COVID syndrome: reCOVer, a cross-over randomized controlled pilot trial. Investigative Ophthalmology & Visual Science<\/em> 66<\/strong>, 1552-1552 (2025).<\/p>\n\n

3\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hohberger, B. et al.<\/em> Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection. Front Med (Lausanne)<\/em> 8<\/strong>, 754667 (2021). https:\/\/doi.org\/10.3389\/fmed.2021.754667<\/a><\/p>\n\n

4\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Stein, S. H. & Phipps, R. P. Antigen-specific IGG2A production in response to prostaglandin E2, immune complexes, and IFN-gamma. The Journal of Immunology<\/em> 147<\/strong>, 2500-2506 (1991). https:\/\/doi.org\/10.4049\/jimmunol.147.8.2500<\/a><\/p>\n\n

5\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fedyk, E. R. & Phipps, R. P. Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. Proc Natl Acad Sci U S A<\/em> 93<\/strong>, 10978-10983 (1996). https:\/\/doi.org\/10.1073\/pnas.93.20.10978<\/a><\/p>\n\n

6\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ishihara, Y. et al.<\/em> Regulation of Immunoglobulin G2 Production by Prostaglandin E<sub>2<\/sub> and Platelet-Activating Factor. Infection and Immunity<\/em> 68<\/strong>, 1563-1568 (2000). https:\/\/doi.org\/doi:10.1128\/iai.68.3.1563-1568.2000<\/a><\/p>\n\n

7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Roper, R. L. & Phipps, R. P. Prostaglandin E2 and cAMP inhibit B lymphocyte activation and simultaneously promote IgE and IgG1 synthesis. J Immunol<\/em> 149<\/strong>, 2984-2991 (1992).<\/p>\n\n

8\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Glynne, P., Tahmasebi, N., Gant, V. & Gupta, R. Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines. J Investig Med<\/em> 70<\/strong>, 61-67 (2022). https:\/\/doi.org\/10.1136\/jim-2021-002051<\/a><\/p>\n\n

9\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Tan, X. et al.<\/em> Histamine directly and synergistically with lipopolysaccharide stimulates cyclooxygenase-2 expression and prostaglandin I(2) and E(2) production in human coronary artery endothelial cells. J Immunol<\/em> 179<\/strong>, 7899-7906 (2007). https:\/\/doi.org\/10.4049\/jimmunol.179.11.7899<\/a><\/p>\n\n

10\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Uotila, P. Inhibition of prostaglandin E2 formation and histamine action in cancer immunotherapy. Cancer Immunology, Immunotherapy<\/em> 37<\/strong>, 251-254 (1993). https:\/\/doi.org\/10.1007\/BF01518519<\/a><\/p>\n\n

11\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 van Berkel, J., Lalieu, R. C., Joseph, D., Hellemons, M. & Lansdorp, C. A. Hyperbaric oxygen therapy for long COVID: a prospective registry. Sci Rep<\/em> 15<\/strong>, 28351 (2025). https:\/\/doi.org\/10.1038\/s41598-025-11539-0<\/a><\/p>\n\n

12\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Wu, B. Q. et al.<\/em> Effects of Hyperbaric Oxygen Therapy on Long COVID: A Systematic Review. Life (Basel)<\/em> 14<\/strong> (2024). https:\/\/doi.org\/10.3390\/life14040438<\/a><\/p>\n\n

13\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Su, J. J., Chen, H. T., Wang, X., Jin, Q. & Wang, L. [The relationship between the expression of PGE2 and COX-2 and the osteogenic activity and oxygen level of alveolar bone]. Shanghai Kou Qiang Yi Xue<\/em> 33<\/strong>, 85-89 (2024).<\/p>\n\n

14\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Niu, K. C., Lin, M. T. & Kao, C. H. Prevention and suppression of pyrogenic fever in rabbits by hyperbaric oxygen. Eur J Pharmacol<\/em> 570<\/strong>, 229-234 (2007). https:\/\/doi.org\/10.1016\/j.ejphar.2007.05.056<\/a><\/p>\n\n

15\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Niu, K. C., Huang, W. T., Lin, M. T. & Huang, K. F. Hyperbaric oxygen causes both antiinflammation and antipyresis in rabbits. Eur J Pharmacol<\/em> 606<\/strong>, 240-245 (2009). https:\/\/doi.org\/10.1016\/j.ejphar.2009.01.013<\/a><\/p>\n\n

16\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Heyboer Rd, M., Wojcik, S. M., Smith, G. & Santiago, W. Effect of hyperbaric oxygen therapy on blood pressure in patients undergoing treatment. Undersea Hyperb Med<\/em> 44<\/strong>, 93-99 (2017). https:\/\/doi.org\/10.22462\/3.4.2017.2<\/a><\/p>\n\n

17\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Wang, L., Wu, Y., Jia, Z., Yu, J. & Huang, S. Roles of EP Receptors in the Regulation of Fluid Balance and Blood Pressure. Front Endocrinol (Lausanne)<\/em> 13<\/strong>, 875425 (2022). https:\/\/doi.org\/10.3389\/fendo.2022.875425<\/a><\/p>\n\n

18\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Oostwouder, C. J. et al.<\/em> Effect of subcutaneous lidocaine-hydroxypropyl-\u03b2-cyclodextrin (HP-\u03b2-CD) on quality of life in patients with post-COVID condition: a 36-week observational interrupted time series study. EClinicalMedicine<\/em> 90<\/strong>, 103681 (2025). https:\/\/doi.org\/10.1016\/j.eclinm.2025.103681<\/a><\/p>\n\n

19\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cook, V. L. et al.<\/em> Anti-inflammatory effects of intravenously administered lidocaine hydrochloride on ischemia-injured jejunum in horses. Am J Vet Res<\/em> 70<\/strong>, 1259-1268 (2009). https:\/\/doi.org\/10.2460\/ajvr.70.10.1259<\/a><\/p>\n\n

20\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Isman, A. et al.<\/em> Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19. Brain Behav Immun Health<\/em> 36<\/strong>, 100733 (2024). https:\/\/doi.org\/10.1016\/j.bbih.2024.100733<\/a><\/p>\n\n

21\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bolton, M. J., Chapman, B. P. & Van Marwijk, H. Low-dose naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Rep<\/em> 13<\/strong> (2020). https:\/\/doi.org\/10.1136\/bcr-2019-232502<\/a><\/p>\n\n

22\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Zhang, X. et al.<\/em> Dissecting the Innate Immune Recognition of Opioid Inactive Isomer (+)-Naltrexone Derived Toll-like Receptor 4 (TLR4) Antagonists. J Chem Inf Model<\/em> 58<\/strong>, 816-825 (2018). https:\/\/doi.org\/10.1021\/acs.jcim.7b00717<\/a><\/p>\n\n

23\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sun, Q., Liu, Q., Zheng, Y. & Cao, X. Rapamycin suppresses TLR4-triggered IL-6 and PGE(2) production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation. Mol Immunol<\/em> 45<\/strong>, 2929-2936 (2008). https:\/\/doi.org\/10.1016\/j.molimm.2008.01.025<\/a><\/p>\n\n

24\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pearson, L. et al.<\/em> Stellate Ganglion Block Relieves Long COVID-19 Symptoms in 86% of Patients: A Retrospective Cohort Study. Cureus<\/em> 15<\/strong>, e45161 (2023). https:\/\/doi.org\/10.7759\/cureus.45161<\/a><\/p>\n\n

25\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Luo, D., Pan, W., Li, Y., Feng, K. & Liu, G. The Interaction Analysis between the Sympathetic and Parasympathetic Systems in CHF by Using Transfer Entropy Method. Entropy (Basel)<\/em> 20<\/strong> (2018). https:\/\/doi.org\/10.3390\/e20100795<\/a><\/p>\n\n

26\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Zhang, Z. H. et al.<\/em> EP\u2083 receptors mediate PGE\u2082-induced hypothalamic paraventricular nucleus excitation and sympathetic activation. Am J Physiol Heart Circ Physiol<\/em> 301<\/strong>, H1559-1569 (2011). https:\/\/doi.org\/10.1152\/ajpheart.00262.2011<\/a><\/p>\n\n

27\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Yokotani, K. et al.<\/em> Elevation of plasma noradrenaline levels in urethane-anaesthetized rats by activation of central prostanoid EP3 receptors. Br J Pharmacol<\/em> 115<\/strong>, 672-676 (1995). https:\/\/doi.org\/10.1111\/j.1476-5381.1995.tb14985.x<\/a><\/p>\n\n

28\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Reinheimer, T., Harnack, E., Racke, K. & Wessler, I. Prostanoid receptors of the EP3 subtype mediate inhibition of evoked [3H]acetylcholine release from isolated human bronchi. Br J Pharmacol<\/em> 125<\/strong>, 271-276 (1998). https:\/\/doi.org\/10.1038\/sj.bjp.0702057<\/a><\/p>\n\n

29\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Deng, J. J. et al.<\/em> Treatment of stellate ganglion block in diseases: Its role and application prospect. World J Clin Cases<\/em> 11<\/strong>, 2160-2167 (2023). https:\/\/doi.org\/10.12998\/wjcc.v11.i10.2160<\/a><\/p>\n\n

30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Zheng, Z. S., Simonian, N., Wang, J. & Rosario, E. R. Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: a pilot study. Frontiers in Neurology<\/em> 15<\/strong> (2024). https:\/\/doi.org\/10.3389\/fneur.2024.1393371<\/a><\/p>\n\n

31\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Revathikumar, P., Ma\u00eetre, E. L., Jakobsson, P.-J., Korotkova, M. & Lampa, J. A2.7\u2005Effects of Vagus Nerve Stimulation on the Central Prostaglandin System and Substance P Following Peripheral Inflammation. Annals of the Rheumatic Diseases<\/em> 72<\/strong>, A6-A7 (2013). https:\/\/doi.org\/https:\/\/doi.org\/10.1136\/annrheumdis-2013-203215.7<\/a><\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Long COVID therapies, tested partially beneficial, linked to EP-receptor profiles Long COVID interventions; PGE2 hypothesis-driven mechanistic explanations \u00a0 Long COVID […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-3391","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pge2-hypothesis.com\/index.php?rest_route=\/wp\/v2\/pages\/3391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pge2-hypothesis.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pge2-hypothesis.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pge2-hypothesis.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pge2-hypothesis.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3391"}],"version-history":[{"count":43,"href":"https:\/\/pge2-hypothesis.com\/index.php?rest_route=\/wp\/v2\/pages\/3391\/revisions"}],"predecessor-version":[{"id":6583,"href":"https:\/\/pge2-hypothesis.com\/index.php?rest_route=\/wp\/v2\/pages\/3391\/revisions\/6583"}],"wp:attachment":[{"href":"https:\/\/pge2-hypothesis.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}